StockNews.com assumed coverage on shares of Arcadia Biosciences (NASDAQ:RKDA – Free Report) in a research report sent to investors on Friday morning. The firm issued a sell rating on the basic materials company’s stock.
Other equities analysts have also recently issued research reports about the company. Lake Street Capital upgraded Arcadia Biosciences to a strong-buy rating in a report on Tuesday, May 14th. HC Wainwright dropped their price target on Arcadia Biosciences from $10.00 to $6.00 and set a buy rating on the stock in a research report on Thursday, May 23rd.
View Our Latest Stock Analysis on RKDA
Arcadia Biosciences Stock Performance
Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) last issued its earnings results on Thursday, May 9th. The basic materials company reported ($1.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.52) by $0.74. Arcadia Biosciences had a negative return on equity of 84.27% and a negative net margin of 129.74%. The firm had revenue of $1.26 million for the quarter, compared to analysts’ expectations of $1.20 million. During the same quarter last year, the business earned ($3.83) earnings per share. As a group, equities analysts forecast that Arcadia Biosciences will post -2.29 EPS for the current year.
About Arcadia Biosciences
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Read More
- Five stocks we like better than Arcadia Biosciences
- When to Sell a Stock for Profit or Loss
- Survey: Top 175 Fittest Retirement Locations in America
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Buy P&G Now, Before It Sets A New All-Time High
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.